Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Multi-institutional outcomes of patients aged 75 years and older with pancreatic ductal adenocarcinoma treated with ablative 5-fraction stereotactic magnetic resonance image-guided adaptive radiation therapy (SMART).
Authors
Michael David Chuong
Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
Michael David Chuong , Russell Palm , Roberto Herrera , Muni Rubens , John Michael Bryant , Sarah E. Hoffe , Dae Won Kim , Adeel Kaiser , Antonio Ucar , Jason B. Fleming , Fernando I. De Zarraga , Pamela Joy Hodul , Santiago Aparo , Horacio Asbun , Mokenge Peter Malafa , Ramon Jimenez , Jason Denbo , Jessica M. Frakes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.569
Abstract #
569
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
KRAS mutation status in the prediction of pancreatic tumor response after neoadjuvant systemic therapy and magnetic resonance-guided SBRT.
First Author: Amit Jethanandani
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Lymphopenia and spleen dose for patients with inoperable pancreatic cancer receiving ablative 5-fraction radiation therapy.
First Author: Michael David Chuong
Poster
2023 ASCO Annual Meeting
A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.
First Author: Richard Tuli
Poster
2022 ASCO Annual Meeting
Sequential treatment with gemcitabine/nab-paclitaxel (GA) and FOLFIRINOX (FFX) followed by stereotactic MRI-guided adaptive radiation therapy (SMART) in patients with locally advanced pancreatic cancer (LAPC): GABRINOX-ART phase 2, multicenter trial.
First Author: Fabienne Portales